Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Adult
Aged
Aged, 80 and over
Albumins
/ administration & dosage
Angiogenesis Inhibitors
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bevacizumab
/ administration & dosage
Disease-Free Survival
Drug Administration Schedule
Endothelial Cells
/ pathology
Erlotinib Hydrochloride
/ administration & dosage
Female
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Middle Aged
Neoplastic Cells, Circulating
/ pathology
Paclitaxel
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Triple Negative Breast Neoplasms
/ blood
Tubulin Modulators
/ administration & dosage
Circulating endothelial cells
Circulating tumor cells
Erlotinib
Metastatic
Nab-paclitaxel bevacizumab
Triple negative breast cancer
Journal
Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
18
09
2018
accepted:
04
12
2018
pubmed:
10
2
2019
medline:
15
4
2020
entrez:
10
2
2019
Statut:
ppublish
Résumé
Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC. We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC. During induction, the patients received nab-paclitaxel 100 mg/m A total of 55 evaluable patients were enrolled. The median PFS and OS for the cohort was 9.1 months (95% confidence interval, 7.2-11.1) and 18.1 months (95% confidence interval, 15.6-21.7), respectively. Of the 53 patients with measurable disease, 39 (74%) had experienced a partial response and 10 (19%) had stable disease using the Response Evaluation Criteria In Solid Tumors. The most common toxicities were uncomplicated neutropenia, fatigue, and neuropathy. Decreased circulating tumor cells from baseline to the first assessment correlated with longer PFS and OS. Nab-paclitaxel and bevacizumab, followed by maintenance targeted therapy with bevacizumab and erlotinib, resulted in PFS similar to that of other trials. Most patients experienced a partial response (74%). Most patients received maintenance therapy (55%), providing a break from cytotoxic chemotherapy.
Identifiants
pubmed: 30737173
pii: S1526-8209(18)30655-4
doi: 10.1016/j.clbc.2018.12.008
pmc: PMC6440867
mid: NIHMS1516655
pii:
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Tubulin Modulators
0
Bevacizumab
2S9ZZM9Q9V
Erlotinib Hydrochloride
DA87705X9K
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e283-e296Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NIH HHS
ID : S10 OD020069
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
Sci Rep. 2015 Oct 27;5:15746
pubmed: 26503902
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Ann Oncol. 2010 Sep;21(9):1765-71
pubmed: 20233745
Br J Cancer. 2008 Jun 3;98(11):1731-5
pubmed: 18506173
Clin Cancer Res. 2008 Dec 1;14(23):7878-83
pubmed: 19047117
Cell. 2012 May 11;149(4):780-94
pubmed: 22579283
J Clin Oncol. 2005 Sep 1;23(25):5892-9
pubmed: 16043829
J Clin Oncol. 2002 May 1;20(9):2310-8
pubmed: 11981002
JAMA Oncol. 2015 Jul;1(4):528-34; quiz 549
pubmed: 26181262
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Am J Clin Oncol. 2010 Dec;33(6):637-45
pubmed: 20023571
Cytometry A. 2007 Feb;71(2):105-13
pubmed: 17226859
Eur J Cancer. 2017 Jan;70:146-155
pubmed: 27817944
Breast Cancer Res Treat. 2012 Nov;136(2):331-45
pubmed: 23073759
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Cancer Treat Rev. 2014 Sep;40(8):960-73
pubmed: 24909311
Clin Cancer Res. 2009 Nov 1;15(21):6639-48
pubmed: 19825949
Am J Cancer Res. 2016 Aug 01;6(8):1609-23
pubmed: 27648353
Eur J Cancer. 2008 Dec;44(18):2799-805
pubmed: 19008097
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Cytokine Growth Factor Rev. 1996 Aug;7(2):133-41
pubmed: 8899291
J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
pubmed: 1688381
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
Clin Breast Cancer. 2012 Jun;12(3):207-14
pubmed: 22520733
Clin Cancer Res. 2009 Dec 15;15(24):7652-7657
pubmed: 19996223
Breast J. 2006 Jul-Aug;12(4):360-2
pubmed: 16848847
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Cancer J. 2010 Jan-Feb;16(1):23-32
pubmed: 20164687
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4331-8
pubmed: 16857808
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
J Breast Cancer. 2017 Jun;20(2):150-159
pubmed: 28690651
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
pubmed: 7612182
J Clin Oncol. 2011 Nov 10;29(32):4286-93
pubmed: 21990397
J Clin Oncol. 2014 Nov 1;32(31):3483-9
pubmed: 24888818
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Cancer. 2007 Jan 1;109(1):25-32
pubmed: 17146782
Cancer Res. 2010 Mar 1;70(5):2085-94
pubmed: 20179196
Mol Cancer Ther. 2007 Feb;6(2):532-41
pubmed: 17308052
J Clin Oncol. 2011 Apr 1;29(10):1252-60
pubmed: 21383283
Transl Oncol. 2016 Oct;9(5):453-457
pubmed: 27751350
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107
pubmed: 27284266
Clin Breast Cancer. 2010 Feb;10(1):81-6
pubmed: 20133263
Lancet. 1987 Jun 20;1(8547):1398-402
pubmed: 2884496